Congress Asset Management CO Atea Pharmaceuticals, Inc. Transaction History

Congress Asset Management CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 21, 2023	BUY	$3.0 - $4.97 $58,200 - $96,418	19,400 Added 10.9%	197,312 $660,000
Q4 2022 Jan 18, 2023	BUY	$4.35 - $6.17 $8,869 - $12,580	2,039 Added 1.16%	177,912 $0
Q3 2022 Nov 08, 2022	BUY	$5.49 - $8.79 $10,046 - $16,085	1,830 Added 1.05%	175,873 $1 Million
Q2 2022 Aug 02, 2022	SELL	$5.33 - $8.18 $37,800 - $58,012	-7,092 Reduced 3.92%	174,043 $1.24 Million
Q1 2022 Apr 20, 2022	BUY	$5.5 - $9.19 $73,969 - $123,596	13,449 Added 8.02%	181,135 $1.31 Million
Q4 2021 Jan 28, 2022	SELL	$7.67 - $44.59 $115 - $668	-15 Reduced 0.01%	167,686 $1.5 Million
Q3 2021 Nov 08, 2021	BUY	$21.33 - $35.06 $286,568 - $471,031	13,435 Added 8.71%	167,701 $5.88 Million
Q2 2021 Aug 05, 2021	BUY	$19.22 - $59.08 $2.19 Million - $6.73 Million	113,891 Added 282.08%	154,266 $3.31 Million
Q1 2021 May 05, 2021	BUY	$41.42 - $88.44 $305,058 - $651,360	7,365 Added 22.31%	40,375 $2.49 Million
Q4 2020 Jan 26, 2021	BUY	$26.36 - $41.78 $870,143 - $1.38 Million	33,010 New	33,010 $1.38 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $270M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Congress Asset Management CO , based on Form 13F filings with the SEC.

Stay updated on Congress Asset Management CO with notifications on news.